ProQR Announces First Quarter 2022 Operating and Financial Results
05 mai 2022 16h30 HE
|
ProQR Therapeutics N.V.
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple...
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022
26 avr. 2022 16h10 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR to Participate in the Kempen Life Sciences Conference
19 avr. 2022 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
13 avr. 2022 07h00 HE
|
ProQR Therapeutics N.V.
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple...
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
04 avr. 2022 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit
23 mars 2022 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
07 mars 2022 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
24 févr. 2022 07h00 HE
|
ProQR Therapeutics N.V.
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022Phase 2/3...
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
11 févr. 2022 07h00 HE
|
ProQR Therapeutics N.V.
Study did not meet primary endpoint nor notable secondary endpoints – no benefit observed in either treatment arm versus shamAdditional analyses to be conducted and presented at a future medical...
ProQR to Present at Upcoming SVB Leerink Conference
07 févr. 2022 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...